Seminars in Hematology
Volume 40, Issue 2 , Pages 163-171 , April 2003

Treatment of gammaherpesvirus-related neoplastic disorders in the immunosuppressed host

References 

  1. Abels C, Karrer S, Baumler W, et al.  Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi's sarcoma. Br J Cancer. 1998;77:1021–1024
  2. Ambinder RF, Robertson KD, Moore SM, et al.  Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol. 1996;7:217–226
  3. Andres E, Maloisel F. Interferon-alpha as first-line therapy for treatment of multicentric Castleman's disease. Ann Oncol. 2000;11:1613–1614
  4. Antinori A, De Rossi G, Ammassari A, et al.  Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol. 1999;17:554–560
  5. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med. 2000;342:1027–1038
  6. Aoki Y, Yarchoan R, Wyvill K, et al.  Detection of viral interleukin-6 in Kaposi sarcoma-associated herpesvirus-linked disorders. Blood. 2001;97:2173–2176
  7. Baiocchi RA, Peng R, Roychowdhury S, et al.  Combination antiviral therapy for EBV-associated primary central nervous system lymphoma. In: Presented at the American Society of Clinical Oncology annual meeting, Orlando, FL. May 18-21, 2002;
  8. Bais C, Santomasso B, Coso O, et al.  G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86–89
  9. Beck JT, Hsu SM, Wijdenes J, et al.  Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330:602–605
  10. Beral V, Peterman T, Berkelman R, et al.  AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805–809
  11. Besson C, Goubar A, Gabarre J, et al.  Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98:2339–2344
  12. Bodsworth NJ, Bloch M, Bower M, et al.  Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2001;2:77–87
  13. Bollard CM, Rossig C, Calonge MJ, et al.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179–3187
  14. Boshoff C, Whitby D, Hatziioannou T, et al.  Kaposi's-sarcoma-associated herpesvirus in HIV-negative Kaposi's sarcoma. Lancet. 1995;345:1043–1044 (letter)
  15. Boulanger E, Agbalika F, Maarek O, et al.  A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J. 2001;2:172–179
  16. Bower M, Portsmouth S, Mandalia S, et al.  HIV-1 related Kaposi's sarcoma (KS) in the highly active antiretroviral therapy (HAART) era. Non-nucleoside reverse transcriptase inhibitors (NNRTI's) are as effective at preventing KS as protease inhibitors (PI's). In: Presented at the Sixth International Conference on Malignancies in AIDS and OtherImmunodeficiencies: Basic, Epidemiologic and Clinical Research, Bethesda, MD. April 22-24, 2002;
  17. Cesarman E, Chang Y, Moore PS, et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186–1191
  18. Chang Y, Cesarman E, Pessin M, et al.  Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266:1865–1869
  19. Chodosh J, Holder VP, Gan YJ, et al.  Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis. 1998;177:1194–1201
  20. Coffey AJ, Brooksbank RA, Brandau O, et al.  Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129–135
  21. Curtis RE, Travis LB, Rowlings PA, et al.  Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood. 1999;94:2208–2216
  22. Davis DA, Rinderknecht AS, Zoeteweij JP, et al.  Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood. 2001;97:3244–3250
  23. Davis CL, Harrison KL, McVicar JP, et al.  Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder. Clin Transplant. 1995;9:53–59
  24. Dean M, Jacobson LP, McFarlane G, et al.  Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res. 1999;59:3561–3564
  25. Dotti G, Fiocchi R, Motta T, et al.  High Toxicity and Low Response Rate after Chemotherapy in Patients With Advanced Stage Posttransplant Lymphoproliferative Disorders. In: Presented at the American Society of Hematology annual meeting, Philadelphia, PA. December 6-10, 2001;
  26. Dupont C, Vasseur E, Beauchet A, et al.  Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS. 2000;14:987–993
  27. Eltom MA, Jemal A, Mbulaiteye SM, et al.  Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. JNCI Cancer Spectrum. 2002;94:1204–1210
  28. Ensoli B, Gendelman R, Markham P, et al.  Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma. Nature. 1994;371:674–680
  29. Errante D, Zagonel V, Vaccher E, et al.  Hodgkin's disease in patients with HIV infection and in the general population: Comparison of clinicopathological features and survival. Ann Oncol. 1994;5(suppl 2):37–40
  30. Frizzera G, Peterson BA, Bayrd ED, et al.  A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol. 1985;3:1202–1216
  31. Funch DP, Brady J, Ko HH, et al.  Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. Recent Results Cancer Res. 2002;159:81–88
  32. Gahn B, Siller-Lopez F, Pirooz AD, et al.  Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer. 2001;93:706–713
  33. Gaidano G, Pastore C, Gloghini A, et al.  Human herpesvirus type-8 (HHV-8) in haematopoietic neoplasia. Leuk Lymphoma. 1997;24:257–266
  34. Gaidano G, Pastore C, Lanza C, et al.  Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. Ann Hematol. 1994;69:281–290
  35. Gallo RC. The enigmas of Kaposi's sarcoma. Science. 1998;282:1837–1839
  36. Gill P, Tsai Y, Rao AP, et al.  Clonality in Kaposi's sarcoma. N Engl J Med. 1997;337:570–571
  37. Grulich AE, Li Y, McDonald AM, et al.  Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS. 2001;15:629–633
  38. Grulich AE, Li Y, McDonald A, et al.  Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16:1155–1161
  39. Hanel M, Fiedler F, Thomas C. Anti-CD20 monoclonal antibody (Rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Onkologie. 2001;24:491–494
  40. Haque T, Taylor C, Wilkie GM, et al.  Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 2001;72:1399–1402
  41. Hoffmann C, Tabrizian S, Wolf E, et al.  Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS. 2001;15:2119–2127
  42. Horwitz SM, Tsai D, Twist C, et al.  Rituximab is effective therapy for post-transplant lymphoproliferative disorder (PTLD) not responding to reduction in immunosuppression: A prospective trial in adults and children. In: Presented at the American Society of Clinical Oncology annual meeting, San Francisco, CA. May 12-15, 2001;
  43. Jaffe ES, Harris NL, Stein H, et al.  World Health Organization Classification of Tumors: Pathology and Genetics: Tumors of Haematopoietic and Lymphoid Tissues. In: Lyon, France: JARC Press; 2001;p. 351
  44. Jenson HB, Leach CT, McClain KL, et al.  Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. Leuk Lymphoma. 1997;27:303–314
  45. Kaplan LD, Straus DJ, Testa MA, et al.  Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641–1648
  46. Kingma DW, Shad A, Tsokos M, et al.  Epstein-Barr virus (EBV)-associated smooth-muscle tumor arising in a post-transplant patient treated successfully for two PT-EBV-associated large-cell lymphomas. Case report. Am J Surg Pathol. 1996;20:1511–1519
  47. Kirova YM, Belembaogo E, Frikha H, et al.  Radiotherapy in the management of epidemic Kaposi's sarcoma: A retrospective study of 643 cases. Radiother Oncol. 1998;46:19–22
  48. Klepfish A, Sarid R, Shtalrid M, et al.  Primary effusion lymphoma (PEL) in HIV-negative patients—A distinct clinical entity. Leuk Lymphoma. 2001;41:439–443
  49. Krown SE, Real FX, Cunningham-Rundles S, et al.  Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med. 1983;308:1071–1076
  50. Levine AM. Epidemiology, clinical characteristics, and management of AIDS-related lymphoma. Hematol Oncol Clin North Am. 1991;5:331–342
  51. Ling SM, Roach M, Larson DA, et al.  Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer. 1994;73:2570–2582
  52. Little R, Pearson D, Gutierrez M, et al.  Dose-adjusted EPOCH chemotherapy (CT) with suspension of antiretroviral therapy (ART) for HIV-associated non-Hodgkin's lymphoma (HIV-NHL). In: Presented at the 4th International AIDS Malignancy Conference, Bethesda, MD. May 16-18, 2000;
  53. Little RF, Yarchoan R. Considerations in the management of HIV infection in patients undergoing antineoplastic chemotherapy. In:  Feigal EG,  Levine AM,  Biggar RJ editor. AIDS-Related Cancers and Their Treatment. New York, NY: Marcel Dekker; 2000;p. 281–330
  54. Little RF, Merced-Galindez F, Humphrey RW, et al.  A clinical trial of cidofovir (CDV) in patients with Kaposi's sarcoma (KS). In: Presented at the 2001 International AIDS Malignancy Conference, Bethesda, MD. April 23-25, 2001;
  55. Little RF, Wyvill KM, Pluda JM, et al.  Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000;18:2593–2602
  56. Liu Z, Savoldo B, Huls H, et al.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res. 2002;159:123–133
  57. Malouf MA, Chhajed PN, Hopkins P, et al.  Anti-viral prophylaxis reduces the incidence of lymphoproliferative disease in lung transplant recipients. J Heart Lung Transplant. 2002;21:547–554
  58. Mariette X, Cazals-Hatem D, Warszawki J, et al.  Lymphomas in rheumatoid arthritis patients treated with methotrexate: A 3-year prospective study in France. Blood. 2002;99:3909–3915
  59. Martin DF, Kuppermann BD, Wolitz RA, et al.  Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. 1999;340:1063–1070
  60. Matsukura T, Yokoi A, Egawa H, et al.  Significance of serial real-time PCR monitoring of EBV genome load in living donor liver transplantation. Clin Transplant. 2002;16:107–112
  61. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al.  Pleural and peritoneal lymphoma among people with AIDS in the United States. J Acquir Immune Defic Syndr. 2002;29:418–421
  62. McClain KL, Leach CT, Jenson HB, et al.  Association of Epstein-Barr Virus with leiomyosarcomas in young people with AIDS. N Engl J Med. 1995;332:12–18
  63. Menke DM, Griesser H, Moder KG, et al.  Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed and not immunosuppressed with methotrexate. Am J Clin Pathol. 2000;113:212–218
  64. Mentzer SJ, Perrine SP, Faller DV. Epstein-Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: Pharmacological re-activation of viral target genes with arginine butyrate. Transpl Infect Dis. 2001;3:177–185
  65. Moore PS, Boshoff C, Weiss RA, et al.  Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274:1739–1744
  66. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis. 1994;26:749–752
  67. Nador RG, Cesarman E, Chadburn A, et al.  Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88:645–656
  68. Nishimoto N, Sasai M, Shima Y, et al.  Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood. 2000;95:56–61
  69. Northfelt DW, Dezube BJ, Thommes JA, et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445–2451
  70. Noy A, Gill P, Scudder D, et al.  Angiogenesis inhibitor IM862 is ineffective against AIDS-KS in a randomized, placebo controlled trial. In: Presented at the Sixth International Conference on Malignancies in AIDS and Other Immunodeficiencies: Basic, Epidemiologic and Clinical Research, Bethesda, MD. April 22-24, 2002;
  71. O'Sullivan CE, Peng R, Cole KS, et al.  Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART. J Med Virol. 2002;67:320–326
  72. Oksenhendler E, Boulanger E, Galicier L, et al.  High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331–2336
  73. Oksenhendler E, Duarte M, Soulier J, et al.  Multicentric Castleman's disease in HIV infection: A clinical and pathological study of 20 patients. AIDS. 1996;10:61–67
  74. Papadopoulos EB, Ladanyi M, Emanuel D, et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–1191
  75. Pluda JM, Wyvill K, Little R, et al.  Preliminary results of a pilot study of the administration of interleukin-12to patients (pts) with AIDS-associated Kaposi's sarcoma (KS). J. Human Virol. 1999;2(abstr 120):200
  76. Rabkin CS, Yang Q, Goedert JJ, et al.  Chemokine and chemokine receptor gene variants and risk of non-Hodgkin's lymphoma in human immunodeficiency virus-I-infected individuals. Blood. 1999;93:1838–1842
  77. Rabkin CS, Janz S, Lash A, et al.  Monoclonal origin of multicentric Kaposi's sarcoma lesions. N Engl J Med. 1997;336:988–993
  78. Raez LE, Patel P, Feun L, et al.  Natural history and prognostic factors for survival in patients with acquired immune deficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL). Crit Rev Oncog. 1998;9:199–208
  79. Raez L, Cabral L, Cai JP, et al.  Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999;15:713–719
  80. Ratner L, Lee J, Tang S, et al.  Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171–2178
  81. Reyes C, Abuzaitoun O, De Jong A, et al.  Epstein-Barr virus-associated smooth muscle tumors in ataxia-telangiectasia: A case report and review. Hum Pathol. 2002;33:133–136
  82. Rivas C, Thlick AE, Parravicini C, et al.  Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53. J Virol. 2001;75:429–438
  83. Roskrow MA, Suzuki N, Gan Y, et al.  Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998;91:2925–2934
  84. Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol. 1998;31:491–497
  85. Savoldo B, Goss J, Liu Z, et al.  Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001;72:1078–1086
  86. Sculley TB, Buck M, Gabrielli B, et al.  A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: A potential therapy for posttransplant lymphoproliferative disease. Transplantation. 2002;73:271–279
  87. Sgadari C, Barillari G, Toschi E, et al.  HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002;8:225–232
  88. Shiroky JB, Frost A, Skelton JD, et al.  Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol. 1991;18:1172–1175
  89. Slobod KS, Taylor GH, Sandlund JT, et al.  Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet. 2000;356:1493–1494
  90. Sparano J, Iee S, Chen M, et al.  Phase II trial of infusional cyclophosphamide, doxorubicin and etoposide (CDE) in HIV-associated non-Hodgkin's lymphoma (NHL): An Eastern Cooperative Oncology Group (ECOG) trial (E1494). In: Presented at the Third Anual AIDS Malignancy Conference, Bethesda, MD. May 1999;p. 26–27
  91. Staskus KA, Sun R, Miller G, et al.  Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999;73:4181–4187
  92. Stevens SJ, Verschuuren EA, Pronk I, et al.  Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165–1171
  93. Suda T, Katano H, Delsol G, et al.  HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int. 2001;51:671–679
  94. Tirelli U, Spina M, Jaeger U, et al.  Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: Preliminary results of a phase I/II study. Recent Results Cancer Res. 2002;159:149–153
  95. Tulpule A, Rarick MU, Kolitz J, et al.  Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann Oncol. 2001;12:457–462
  96. Vaccher E, Spina M, di Gennaro G, et al.  Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer. 2001;91:155–163
  97. Van Esser JW, Niesters HG, Van Der Holt B, et al.  Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99:4364–4369
  98. Volberding PA, Abrams DI, Conant M, et al.  Vinblastine therapy for Kaposi's sarcoma in the acquired immunodeficiency syndrome. Ann Intern Med. 1985;103:335–338
  99. Walker RC, Marshall WF, Strickler JG, et al.  Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346–1353
  100. Welles L, Saville MW, Lietzau J, et al.  Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. J Clin Oncol. 1998;16:1112–1121
  101. Weninger W, Partamen TA, Breiteneder-Geleff S, et al.  Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest. 1999;79:243–251
  102. Wilson W, Gutierrez M, Raffeld M, et al.  Lymphomatioid granulomatosis: Phase II study of dose-adjusted interferon-α or EPOCH chemotherapy. Blood. 1999;94(suppl 1, abstr 2668):599a
  103. Wilson WH, Kingma DW, Raffeld M, et al.  Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood. 1996;87:4531–4537
  104. Yarchoan R, Little RF. Immunosuppression-related malignancies. In: ed 6.  DeVita VT,  Hellman S,  Rosenberg SA editor. Cancer, Principles and Practice of Oncology. Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 2575–2597
  105. Yarchoan R. Therapy for Kaposi's sarcoma: Recent advances and experimental approaches. J Acquir Immune Defic Syndr. 1999;21(suppl 1):S66–S73

☆ This is a US government work. There are no restrictions on its use.

☆☆ 0037-1963/03/4002-0007$0.00/0

PII: S0037-1963(03)70008-0

Seminars in Hematology
Volume 40, Issue 2 , Pages 163-171 , April 2003

Article Tools